

Søgeprotokol for opdatering på NKR Nationale Kliniske Retningslinjer

Projekttitel/aspekt	NKR for Psoriasis – Guidelines (version 2019)
Projektgruppe	Jeanett
Søgespecialist	Kirsten Birkefoss
Senest opdateret	07.02.2019

Baggrund	<p>I Danmark lever 2-3 % af den danske befolkning - dvs. cirka 150.000 danskere - med den kroniske sygdom psoriasis. Cirka en fjerdedel af disse (37.500) lider af moderat til svær psoriasis. Psoriasis kan debutere i alle aldre, men debuterer hyppigst enten i 15-30 års eller i 40-60-årsalderen. Diagnosen er baseret på typiske kliniske fund såsom velafgrænsede plaques på huden med rødme, fortykkelse af huden og skældannelse. I daglig klinisk praksis er svær psoriasis defineret som involvering af minimum 10 % af kroppens overflade, mens moderat psoriasis involverer 3-10 % og mild psoriasis involverer under 3 % af kroppens overflade. Tre ud af fire psoriasispatienter har sygdommen i mild form; den sidste fjerdedel har moderat til svær psoriasis. Psoriasis er en immunologisk sygdom, som ikke kun rammer huden, men også leder til en systemisk inflammation, som kan påvirke andre dele af kroppen. Der kan være stor periodisk variation i sygdomstilstanden for den enkelte patient, men de fleste patienter med svær psoriasis må forvente livslang behandling og ofte prøve flere forskellige behandlingsregimer (topikal behandling, lys, tabletbehandling og biologisk behandling). Op til 20 % af patienter med svær psoriasis udvikler psoriasisgigt, der som oftest vil kræve reumatologisk diagnostik og behandling sideløbende med behandlingen hos dermatologen. Dertil kommer, at patienter med svær psoriasis har en øget dødelighed sammenlignet med normalbefolkningen, og har i gennemsnit 4 års kortere levetid (Gelfand, 2006) 1. Dette er specielt grundet hjerte-karsygdomme. Herudover er der ved psoriasis en øget forekomst af andre risikofaktorer for hjerte-karsygdom, herunder diabetes, højt blodtryk, forhøjet kolesteroltal og overvægt. 2 Der er i studier tillige fundet en øget forekomst af depression hos psoriasispatienter. Alt i alt påvirker psoriasis således livskvaliteten på forskellig vis. Psoriasis udgør en betydelig sygdomsbyrde og patienter med psoriasis kan som det fremgår, være i behandling hos flere forskellige speciallæger i forskellige sektorer af sundhedsvæsenet. Patienterne oplever store variationer i behandlingspraksis. Der savnes generelt overordnede retningslinjer og systematik for behandlingsmål, kontrol og opfølgning af psoriasis-patienter, bl.a. med henblik på risikofaktorer for følgesygdomme. På baggrund af ovenstående vurderer Sundhedsstyrelsen, at en national klinisk retningslinje vil være et egnet redskab, der kan understøtte en mere systematisk og evidensbaseret praksis for behandling og opfølgning af patienter med psoriasis med henblik på opsporing af følgesygdomme. Derudover kan retningslinjen være med til at understøtte en høj faglig kvalitet af indsatserne på tværs af lægelige specialer og sektorer således at patienten vil kunne møde et mere optimalt og ensartet behandlings- og opfølgningstilbud, uafhængigt af bopæl.</p>
Generelle søgetermer	<p>Engelske: psoriasis, psoriatic, postulosis palmaris, arthritis psoriatic, pustulosis Palms, Palmoplantaris Pustulosis, Psoriasis</p> <p>Danske: psoriasis, psoriatic, postulosis palmaris, arthritis psoriatic, pustulosis of Palms, Pustulosis Palmaris, Palmoplantaris Pustulosis, Psoriasis, psoriasisartrit</p>

	<p>Norske: psoriasis, psoriatic, postulosis palmaris, arthritis psoriatic, pustulosis of Palms, Pustulosis Palmaris, Palmoplantaris Pustulosis, Psoriasis, psoriasisartritt</p> <p>Svenske: psoriasis, psoriatic, postulosis palmaris, arthritis psoriatic, pustulosis of Palms, Pustulosis Palmaris, Palmoplantaris Pustulosis, Psoriasis, psoriasisartrit</p>
Inklusjons- og eksklusjonskriterier	<p>Sprog: Engelsk, dansk, norsk og svensk</p> <p>År: 2015-2019</p> <p>Population: Alle</p> <p>Publikasjonstyper: Guidelines, MTV, Cochrane Reviews</p>

Informationskilder

Databaser	Interface	Fund	Dato for søgning
G-I-N International	http://www.g-i-n.net/	3	02.02.2019
NICE (UK)	http://www.nice.org.uk/	15	02.02.2019
Trip Database	https://www.tripdatabase.com/	11	02.02.2019
Scottish Intercollegiate Guidelines Network (SIGN)	http://sign.ac.uk	0	02.02.2019
HTA Databasen (CRD database)	http://www.crd.york.ac.uk/CRDWeb/	19	02.02.2019
SBU, Sverige	http://www.sbu.se	2	02.02.2019
Socialstyrelsen, Sverige	http://www.socialstyrelsen.se	1	02.02.2019
Helsedirektoratet, Norge	https://helsedirektoratet.no/	0	02.02.2019
FHI, Norge	http://www.fhi.no/	5	02.02.2019
NHMRC, Australien	https://www.clinicalguidelines.gov.au/	0	02.02.2019
Canadian Medical Association, Canada	https://joulecma.ca/cpg/homepage	2	02.02.2019
American College of Rheumatology	https://www.rheumatology.org	1	02.02.2019
American Academy of Dermatology	http://www.dsog.dk/	1	02.02.2019
EULAR	https://www.eular.org	1	02.02.2019

MEDLINE	OID	202	07.02.2019
EMBASE	OID	553	07.02.2019
PSYCINFO	OID	1	07.02.2019
CINAHL	EBSCO	59	07.02.2019

Note:

- Guidelines fra firmaet Hayes er fra valgt for denne NKR
- Søgetermer og inklusions- og eksklusionskriterier er tilpasset de enkelte databaser.
- Dubletter er så vidt muligt frasorteret ved hjælp af Covidence. De fundne referencer overføres til fagkonsulenten i Covidence.
- Fuldtekster præsenteres i Covidence i pdf-format eller som link
- Søgestrategi for hver enkelt database præsenteres – hvis muligt vises det eksplicit hvor mange referencer den enkelte søgestreng genererer
- Covidence = webbaseret referencehåndteringssystem og kvalitetsvurderingsværktøj
- MAGIC = online skabelonværktøj til guidelines

Søgestrategi

GIN

Søgt på: Psoria* OR (pustulo* AND palm*)

3 fund

Therapie der Psoriasis vulgaris. S3-LL (DDG) [treatment of psoriasis vulgaris]	AWMF (DE) - Association of Scientific Medical Societies	Guideline	Oct 01, 2017	Germany	Published
Therapie der Psoriasis vulgaris bei Kindern und Jugendlichen. S2k-LL (DDG) [Therapy of psoriasis vulgaris in children and adolescents]	AWMF (DE) - Association of Scientific Medical Societies	Guideline	Mar 31, 2019	Germany	In development
Spondyloarthritis in over 16s: diagnosis and management (NG65)	NICE (UK) - National Institute for Health and Care Excellence	Guideline	Feb 01, 2017	United Kingdom	Published

NICE

Søgt på: NICE →NICE Guidance →Conditions and diseases →Skin conditions →Psoriasis

15 fund

1. [Psoriasis](#)
Product type:
Pathway

Last updated:

12 June 2018

2. **Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)**

Product type:

Guidance

Programme:

Technology appraisal guidance

Published date:

3 October 2018

3. **Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)**

Product type:

Guidance

Programme:

Technology appraisal guidance

Published date:

8 August 2018

4. **Guselkumab for treating moderate to severe plaque psoriasis (TA521)**

Product type:

Guidance

Programme:

Technology appraisal guidance

Published date:

13 June 2018

5. **Brodalumab for treating moderate to severe plaque psoriasis (TA511)**

Product type:

Guidance

Programme:

Technology appraisal guidance

Published date:

21 March 2018

6. **Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)**

Product type:

Guidance

Programme:

Technology appraisal guidance

Published date:

6 September 2017

7. **Psoriasis: assessment and management (CG153)**

Link til evidens: <https://www.nice.org.uk/guidance/cg153/evidence>

Product type:

Guidance

Programme:

Clinical guideline

Last updated:

1 September 2017

Published date:
24 October 2012

8. [Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people \(TA455\)](#)

Product type:
Guidance

Programme:
Technology appraisal guidance

Published date:
12 July 2017

9. [Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs \(TA445\)](#)

Product type:
Guidance

Programme:
Technology appraisal guidance

Published date:
24 May 2017

10. [Ixekizumab for treating moderate to severe plaque psoriasis \(TA442\)](#)

Product type:
Guidance

Programme:
Technology appraisal guidance

Published date:
26 April 2017

11. [Ustekinumab for the treatment of adults with moderate to severe psoriasis \(TA180\)](#)

Product type:
Guidance

Programme:
Technology appraisal guidance

Last updated:
3 March 2017

Published date:
23 September 2009

12. [Ustekinumab for treating active psoriatic arthritis \(TA340\)](#)

Product type:
Guidance

Programme:
Technology appraisal guidance

Last updated:
3 March 2017

Published date:
4 June 2015

13. [Apremilast for treating active psoriatic arthritis \(TA433\)](#)

Product type:

Guidance

Programme:

Technology appraisal guidance

Published date:

22 February 2017

14. [Apremilast for treating moderate to severe plaque psoriasis \(TA419\)](#)

Product type:

Guidance

Programme:

Technology appraisal guidance

Published date:

23 November 2016

15. [Secukinumab for treating moderate to severe plaque psoriasis \(TA350\)](#)

Product type:

Guidance

Programme:

Technology appraisal guidance

Published date:

22 July 2015

Trip Database

Søgt på: Psoriasis, Psoriatic

11 fund

[Biologic therapy for psoriasis](#)

Biologic therapy for **psoriasis** British Association of Dermatologists FULL VERSION Guidelines for biologic therapy for **psoriasis** Methods, evidence and recommendations April 2017 NICE has renewed accreditation of the process used by the British Association of Dermatologists to produce clinical guidelines. The renewed accreditation is valid until 31 May 2021 and applies to guidance produced using the processes described in Updated guidance for writing a British Association of Dermatologists (...): Evidence tables clinical studies 227 Appendix F: Forest plots 296 Appendix G: Stakeholders 342 Appendix H: Study selection flow charts 343 Appendix I: GRADE tables 349 Appendix J: Choice of biologic treatment for **psoriasis** (decision aid) 385 Appendix K: Groups at increased risk of tuberculosis, hepatitis B, hepatitis C and HIV 389 British Association of Dermatologists guidelines for biologic therapy for **psoriasis** 2017 1 Guideline Development Group members Name Role CLINICAL Ms Tracy Bale British 2017 *British Association of Dermatologists*

[Psoriasis: assessment and management](#)

Psoriasis: assessment and management **Psoriasis**: assessment and management **Psoriasis**: assessment and management Clinical guideline Published: 24 October 2012 nice.org.uk/guidance/cg153 © NICE 2018. All rights reserved. Subject to Notice of rights (<https://www.nice.org.uk/terms-and-conditions#notice-of-rights>).YY our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When (...) with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

Psoriasis: assessment and management (CG153) © NICE 2018. All rights reserved. Subject to Notice of rights (<https://www.nice.org.uk/terms-and-conditions#notice-of-rights>). Page 2 of 57 Contents Contents Overview 4 Who is it for? 4 Introduction 5 Patient

2012 *National Institute for Health and Clinical Excellence - Clinical Guidelines*

[Spondyloarthritis in over 16s: diagnosis and management](#)

present in healthcare settings. It also provides advice on the range of treatments available. In June 2017, we updated recommendation 1.2.7 to clarify the advice on what imaging should be done. NICE has also produced guidelines on **psoriasis** and low back pain and sciatica in over 16s. Who is it for? Healthcare professionals Commissioners and providers People with spondyloarthritis and their families and carers Spondyloarthritis in over 16s: diagnosis and management (NG65) © NICE 2018. All rights (...), enthesitis and dactylitis) or extra-articular (for example, uveitis and **psoriasis** [including psoriatic nail symptoms]). Risk factors include recent genitourinary infection and a family history of spondyloarthritis or **psoriasis**. 1.1.3 Be aware that axial and peripheral spondyloarthritis may be missed, even if the onset is associated with established comorbidities (for example, uveitis, **psoriasis**, inflammatory bowel disease [Crohn's disease or ulcerative colitis], or a gastrointestinal or genitourinary

2017 *National Institute for Health and Clinical Excellence - Clinical Guidelines*

[British Association of Dermatologists and British photodermatology Group guidelines for topical photodynamic therapy](#)

porokeratosis, alopecia areata, angio?broma, cuta- neous leishmaniasis, Darier disease, erythrasma, folliculitis, fungal infections, granuloma annulare, hypertrophic scars, keratoacanthoma, lichenoid dermatoses, molluscum conta- giosum, morphea and localized scleroderma, interdigital mycoses, necrobiosis lipoidica, perioral dermatitis, pho- torejuvenation, porokeratosis, **psoriasis**, radiodermatitis, rosacea, sebaceous hyperplasia, viral warts, vulval lichen sclerosus, vulvodynia, wound healing and Zoon (...) transplant patients. b Including acne, actinic cheilitis, disseminated super?cial actinic porokeratosis, alopecia areata, angio?broma, cutaneous leishmaniasis, Darier disease, erythrasma, fol- liculitis, fungal infections, granuloma annulare, hypertrophic scars, keratoacanthoma, lichenoid dermatoses, molluscum contagiosum, mor- phea and localized scleroderma, interdigital mycoses, necrobiosis lipoidica, perioral dermatitis, photorejuvenation, porokeratosis, **psoriasis**, radiodermatitis, rosacea, sebaceous

2019 *British Association of Dermatologists*

[British Association of Dermatologists' guidelines for the management of lichen sclerosus](#)

intraepithelial neoplasia. Another differential diagnosis is vitiligo, but this does not cause any architectural change and is asymptomatic; however, vitiligo may coexist with LS. ? Is there an additional superimposed problem such as the development of a contact allergy to the medication (refer for patch testing), urinary incontinence (refer for urologi- cal advice), herpes simplex infection or candidiasis (treat infection appropriately)? Some patients can have LS and **psoriasis** together, which may be more dif

2018 *British Association of Dermatologists*

[The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis](#)

* Monitoring Monitor* Test* Connective tissue disease Drug induced vasculitis Drug AND induced AND lupus Drug induced lupus Haematological disorders Anaemia Neutropenia Pancytopenia Aplastic anaemia Lymphopeni* Thrombocytopeni* **Psoriasis** Drug induced **psoriasis** Peri-operative period Postoperative infection Surgery + infection Other terms Elderly Geriatric* Care of the elderly Mortality Safety Topic Search terms used in addition to either: 'Rheumatoid + arthritis', 'Ankylosing spondylitis', 'Seronegative (...) induced vasculitis Drug AND induced AND lupus Drug induced lupus Haematological disorders Anaemia Neutropenia Pancytopenia Aplastic anaemia Lymphopeni* Thrombocytopeni* **Psoriasis** Drug induced **psoriasis** Peri-operative period Postoperative infection Surgery + infection Other terms Elderly Geriatric* Care of the elderly Mortality Safety T able 3 Search terms used for literature review Topic Search terms used in addition to either: 'Rheumatoid + arthritis', 'Ankylosing spondylitis', 'Seronegative

Full Text available with Trip Pro

2018 British Society for Rheumatology

[Guidelines on the measurement of ultraviolet radiation levels in ultraviolet phototherapy](#)

of the British Association of Dermatologists (BAD): www.bad.org.uk. 2.0 Stakeholder involvement and peer review The guideline development group consisted of clinical scientists, consultant dermatologists and a nurse practitioner. The draft document was circulated for comments to the BAD membership, the British Photodermatology Group (BPG) membership, the British Dermatological Nursing Group, the Primary Care Dermatological Society, the Institute of Physics and Engineering in Medicine, the **Psoriasis** (...) Association, the **Psoriasis** and Psoriatic Arthritis Alliance, and a patient, and peer-reviewed by the Clinical Standards Unit of the BAD (consisting of the Therapy and Guidelines Subcommittee) prior to publication. 3.0 Methodology This set of guidelines has been developed using the BAD's recommended methodology, 1 and with reference to the Appraisal NICE has accredited the process used by the British Association of Dermatologists to produce guidelines. Accreditation is valid for 5 years from May 2010

2015 British Association of Dermatologists

[British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen ultraviolet A \(PUVA\) therapy](#)

Stakeholder involvement and peer review The initial guideline development group (GDG) consisted of consultant dermatologists, a medical physicist, a nurse phototherapist and a clinical fellow in medical dermatology. The draft document was circulated to the BAD membership, the British Photodermatology Group (BPG) membership, the British Dermatological Nursing Group, the National Eczema Society, the Vitiligo Society, the **Psoriasis** Association, and the **Psoriasis** and Psoriatic Arthritis Alliance (...) has been in use with refined psoralens since the early 1950s. 4 Its use has declined somewhat as narrowband ultraviolet B (NB-UVB) replaced less effective broadband ultraviolet B (BB-UVB) sources to treat **psoriasis**, and as NB-UVB has been proved more effective than PUVA in treating vitiligo. 5,6 It remains an important treatment, being the first-line phototherapy for pityriasis rubra pilaris and plaque-stage mycosis fungoides (MF), and a good second-line phototherapy for common chronic

2016 British Association of Dermatologists

[American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis](#)

American College of Rheumatology/National **Psoriasis** Foundation Guideline for the Treatment of Psoriatic Arthritis 1 Arthritis & Rheumatology Vol. 0, No. 0, Month 2018, pp 1–28 DOI 10.1002/art.40726 © 2018, American College of Rheumatology SPECIAL ARTICLE 2018 American College of Rheumatology/National **Psoriasis** Foundation Guideline for the Treatment of Psoriatic Arthritis Jasvinder A. Singh, 1 Gordon Guyatt, 2 Alexis Ogdie, 3 Dafna D. Gladman, 4 Chad Deal, 5 Atul Deodhar, 6 Maureen Dubreuil, 7 (...) Michael Siegel, 28 Jessica A. Walsh, 29 Amy S. Turner, 19 and James Reston 20 Objective. To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National **Psoriasis** Foundation (NPF). Methods. We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A Literature Review Team performed

2019 American College of Rheumatology

[British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017.](#)

British Association of Dermatologists guidelines for biologic therapy for **psoriasis** 2017. British Association of Dermatologists guidelines for biologic therapy for **psoriasis** 2017. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites (...) therapy for **psoriasis** 2017. Smith CH, Jabbar-Lopez ZK, Yiu ZZ, Bale T,

Burden AD, Coates LC, Cruickshank M, Hadoke T, MacMahon E, Murphy R, Nelson-Piercy C, Owen CM, Parslew R, Peleva E, Pottinger E, Samarasekera EJ, Stoddart J, Strudwicke C, Venning VA, Warren RB, Exton LS, Mohd Mustapa MF. British Association of Dermatologists guidelines for biologic therapy for **psoriasis** 2017. Br J Dermatol. 2017 Sep;177(3):628-36. [17 references] This is the current release of the guideline. This guideline updates

2017 [National Guideline Clearinghouse \(partial archive\)](#)

[Guidelines of care for the management of psoriasis and psoriatic arthritis Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions](#)

Guidelines of care for the management of **psoriasis** and psoriatic arthritis Section 6. Guidelines of care for the treatment of **psoriasis** and psoriatic arthritis: Case-based presentations and evidence-based conclusions FROM THE ACADEMY Guidelines of care for the management of psoriasis and psoriatic arthritis Section 6. Guidelines of care for the treatment of **psoriasis** and psoriatic arthritis: Case-based presentations and evidence-based conclusions Work Group: Chair, Alan Menter, MD, a Neil J. Korman, MD (...), Massachusetts; San Francisco and Palo Alto, California; New York, New York; St Louis, Missouri; and Detroit, Michigan **Psoriasis** is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In the first 5 parts of the American Academy of Dermatology **Psoriasis** Guidelines of Care, we have presented evidence supporting the use of topical treatments, phototherapy, traditional systemic agents, and biological therapies for patients

2011 [American Academy of Dermatology](#)

SIGN

Søgt på alle emner

0 fund

HTA database

Søgt på: (psoria* or (pustulo* and hand*)) AND (guideline* or hta or health technology assessment*) IN HTA FROM 2015 TO 2019

19 fund (findes i Covidence)

SBU (Sverige)

Søgt på: psoriasis

2 fund

SBU:s rapporter visar det samlade vetenskapliga underlaget

SBU har utarbetat fullständiga utvärderingsrapporter inom områdena endometrios, epilepsi och psoriasis. Jämfört med underlagen för nationella riktlinjer innehåller SBU-rapporterna utökad information, bland annat

en beskrivning av metodiken för den systematiska översikten, etik, diskussion och överväganden för forskning.

SBU:s utvärderingar följer en väl genomarbetad och noggrann metod där sakkunniga inom området gör ett omfattande och noggrant arbete genom att systematiskt söka, sälla, kvalitetsgranska och väga samman forskningsresultat från hela världen. SBU:s utvärderingar används som ett opartiskt och vetenskapligt tillförlitligt underlag för andra myndigheter, men även för forskare, brukare och anhöriga. SBU:s rapporter lyfter fram slutsatser, men ger inte några rekommendationer eller riktlinjer.

Vetenskapligt underlag i förhållande till rekommendationer

Ett starkt vetenskapligt underlag innebär inte alltid en stark rekommendation. Den instans som tar fram en rekommendation väger in mer än det vetenskapliga underlaget i sitt beslut. Som exempel kan nämnas ekonomiska aspekter, hur genomförbar en viss åtgärd är samt tillgängligheten till den metod eller behandling det gäller.

Samtliga de vetenskapliga underlag som SBU lämnat under arbetet med nationella riktlinjer för endometrios, epilepsi är tillgängliga via SBU:s registrator (registrator@sbu.se).

Psoriasis

Vetenskapligt underlag till Socialstyrelsens nationella riktlinjer

Till remissversionen av Socialstyrelsens nationella riktlinjer för psoriasis

Till det vetenskapliga underlaget som SBU lämnat under arbetet med nationella riktlinjer

Underlaget till nationella riktlinjer tar, utöver de behandlingar som ingår i SBU:s utvärderingsrapport (se nedan), upp några topikala behandlingar av psoriasis på särskilt svårbehandlad hudyta. Exempel är psoriasis i hårbotten eller på naglar.

SBU:s utvärderingsrapport

SBU:s utvärderingsrapport tar upp ljusbehandling- och systemisk behandling av medelsvår och svår psoriasis i huden.

[Till SBU:s utvärderingsrapport Ljusbehandling och systemisk behandling av psoriasis](#)

Socialstyrelsen (Sverige)

Søgt i menuen på: Nationella riktlinjer

1 fund

Nationella riktlinjer för vård vid psoriasis

-  [Ladda ner sida](#)

Nu är de nationella riktlinjerna för psoriasis publicerade i en remissversion. Riktlinjerna kommer att vara ett stöd för dem som fattar beslut om hur resurserna ska fördelas inom vård av personer med psoriasis.

[Ladda ner eller beställ rapporten Nationella riktlinjer för vård vid psoriasis – Stöd för styrning och ledning – Remissversion](#). Rapporten fokuserar på de rekommendationer i riktlinjerna som bedöms vara särskilt viktiga ur ett styr- och ledningsperspektiv.

- Riktlinjerna är publicerades i en remissversion den 12 mars och rekommendationerna blir gällande från och med detta datum. Du har möjlighet att lämna synpunkter fram till och med den 31 maj 2018 via mejl: nr-psoriasis@socialstyrelsen.se.
- [Sök i rekommendationerna](#)
- Den slutliga versionen kommer att publiceras under våren 2019.

Uppföljning av riktlinjerna

Under 2018 genomför Socialstyrelsen en utvärdering, som kommer att publiceras under 2019. Socialstyrelsen kommer även att utreda förutsättningarna för att ta fram målnivåer inom området.

Helsedirektoratet

Søgt på: Nasjonale faglige retningslinjer

0 fund

Folkehelseinstituttet

Søgt på hver af ordene:

Psoriasis, psoriasisartritt

5 fund

1.

METODEVURDERING

TNF-hemmere og efalizumab ved behandling av hudsykdommer

[Vi har foretatt en systematisk gjennomgang av kunnskapsgrunnet om effekt og sikkerhet ved bruk av TNF-alfa-hemmere og efalizumab ved hudsykdommer.](#)

[PUBLISERT 03.10.2014](#)

2.

ARTIKKEL

Kosmetisk eller medisinsk bruk av optisk stråling

[Mange behandlingsformer benytter optisk stråling.](#)

[PUBLISERT 02.03.2015 OPPDATERT 24.02.2016](#)

3.

METODEVURDERING

TNF-hemmere ved revmatiske sykdommer

[Denne rapporten er første del av et oppdrag fra Helse- og omsorgsdepartementet og Helse Nord RHF med fokus på effekt og bivirkninger ved bruk av TNF-hemmere.](#)

PUBLISERT 21.04.2008 OPPDATERT 09.09.2014

4.

METODEVURDERING

TNF-hemmere ved revmatiske sykdommer (del 3): Helseøkonomi

Vi utførte en systematisk oversikt over publiserte økonomiske evalueringer av TNF-hemmere mot RA.

PUBLISERT 24.04.2008 OPPDATERT 09.09.2014

5.

ARTIKKEL

3.7 Medikamenter brukt som forebygging

PUBLISERT 06.01.2014 OPPDATERT 23.03.2018

NHMRC, Australien

Søgt på: **Psoriasis**, Psoriatic

0 fund

Guidelines, Canadian Medical Association, Canada

Søgt på: Psoriasis, Psoriatic (fulltext search)

2 fund

1. Canadian guideline for the management of plaque psoriasis

Canadian Psoriasis Guidelines Committee

Published on: 2009, Last revision: 2016

[Details](#)

2. 2016 Addendum to the Canadian guidelines for the management of plaque psoriasis 2009

Canadian Psoriasis Guidelines Committee

Published on: 2016

[Details](#)

American College of Rheumatology

Søgt på: Psoriasis, Psoriatic

1 fund

<https://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines/Psoriatic-Arthritis>

American Academy of Dermatology

Søgt på: Psoriasis, psoriatic

1 fund

<https://www.aad.org/practicecenter/quality/clinical-guidelines/psoriasis>

EULAR

Søgt på: Psoriasis

1 fund

L Gossec, J S Smolen, S Ramiro, M de Wit, M Cutolo, M Dougados, P Emery, R Landewé, S Oliver, D Aletaha, N Betteridge, J Braun, G Burmester, J D Cañete, N Damjanov, O FitzGerald, E Haglund, P Helliwell, T K Kvien, R Lories, T Luger, M Maccarone, H Marzo-Ortega, D McGonagle, I B McInnes, I Olivieri, K Pavelka, G Schett, J Sieper, F van den Bosch, D J Veale, J Wollenhaupt, A Zink, D van der Heijde

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

Ann Rheum Dis doi:10.1136/annrheumdis-2015-208337

[Read recommendation](#)

Ann Rheum Dis 2016;75:490-498 doi:10.1136/annrheumdis-2015-208466

Medline

202 fund (findes I Covidence)

Database(s): **Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R)** 1946 to February 05, 2019

Search Strategy:

#	Searches	Results
1	exp Psoriasis/	36968
2	psoria*.ti,ab,kw,kf.	44576
3	(pustulo* adj3 palm*).ti,ab,kw,kf.	803

4	or/1-3	50260
5	Health planning guidelines/	4020
6	Guidelines as topic/ or Practice guidelines as topic/	145237
7	(Guideline or Practice guideline).pt.	31502
8	(Guideline* or practice guideline* or clinical guideline* or guidance or consensus or recommendations).ti,kw,kf,pt.	155637
9	cochrane.jw.	14150
10	or/5-9	272184
11	4 and 10	675
12	limit 11 to (yr="2015-2019" and (english or danish or norwegian or swedish))	202

Embase

553 fund (findes I Covidence)

Database(s): **Embase** 1974 to 2019 February 06

Search Strategy:

#	Searches	Results
1	exp Psoriasis/	77846
2	psoria*.ti,kw.	45385
3	(pustulo* adj3 palm*).ti,kw.	665
4	or/1-3	79382
5	Practice guideline/	367476
6	(Guideline* or practice guideline* or clinical guideline*).ti,kw.	109244
7	cochrane.jx.	21082
8	or/5-7	424020
9	4 and 8	1430
10	limit 9 to (yr="2015-2019" and (english or danish or norwegian or swedish))	553

PsycINFO

1 fund (findes I Covidence)

Database(s): **PsycINFO** 1806 to February Week 1 2019

Search Strategy:

# Searches	Results
1 psoria*.ti,ab,id.	598
2 (pustulo* and palm*).ti,ab,id.	2
3 1 or 2	600
4 exp Treatment Guidelines/ or guideline*.ti,id.	15408
5 3 and 4	7
6 limit 5 to (yr="2015-2019" and (english or danish or norwegian or swedish))	1

Cinahl

59 fund (findes I Covidence)

#	Query	Limiters/Expanders	Results
S8	S4 AND S7	Limiters - Published Date: 20150101-20190231; Language: Danish, English, Norwegian, Swedish	59
S7	S5 or S6		68,102
S6	TI (Guideline* or guidance or consensus or recommendations)		62,498
S5	PT practice guidelines		11,222
S4	S1 or S2 or S3		8,386
S3	pustulo* and palm*		65
S2	psoriasis or psoriatic*		8,369
S1	(MH "Psoriasis+")		6,237
